Publication date: Jul 09, 2025
Emerging evidence suggests gut microbiota differences in Parkinson’s Disease (PD) may impact disease progression and treatment. Faecal Microbiota Transplantation (FMT) offers a potential therapeutic approach. We conducted an open-label pilot study to assess the safety, tolerability, and symptom impact of FMT in 12 patients with mild to moderate PD, administered via enema for 6 months. FMT was safe and well tolerated, causing only mild, transient gastrointestinal symptoms. While no significant motor symptom changes were observed, there was a trend toward reduced daily OFF time at 2 months. Whilst no sustained improvement in non-motor symptoms was found after 6 months, transient improvements in quality of life and non-motor scores were noted at 2 months; these gains regressed by study end. Overall, extended FMT therapy in PD appears safe and tolerable, with reduction in daily motor OFF time and self-reported non-motor symptoms that was not sustained throughout the 6-months of treatment.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Daily | Faecal |
| Gastrointestinal | Fmt |
| Microbiota | Microbiota |
| Parkinson | Mild |
| Pilot | Months |
| Motor | |
| Non | |
| Parkinson | |
| Pd | |
| Pilot | |
| Safety | |
| Symptom | |
| Symptoms | |
| Tolerability | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s disease |
| disease | MESH | disease progression |
| disease | MESH | synucleinopathy |
| disease | MESH | tremor |
| disease | MESH | pathogenesis |
| disease | MESH | dysbiosis |
| disease | MESH | Movement Disorders |
| disease | MESH | Gait |
| drug | DRUGBANK | Methionine |
| disease | MESH | Hypertension |
| disease | MESH | Depression |
| disease | MESH | Anxiety |
| drug | DRUGBANK | Nitazoxanide |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Spinosad |
| drug | DRUGBANK | Isoxaflutole |
| disease | MESH | mild cognitive impairment |